Lipid Antiviral Conjugate Technology

Chimerix is applying its powerful Lipid-Antiviral-Conjugate Technology to existing antiviral compounds with the goal of increasing their bioavailability, tolerability and activity.  By improving the pharmaceutical attributes of drugs with known mechanisms of action to create new chemical entities, we believe we can dramatically change the way certain deadly viral diseases are treated.

Chimerix’s proprietary technology is used to covalently modify a drug molecule so that it mimics a naturally occurring phospholipid metabolite. The lipid mimic can then utilize natural uptake pathways to achieve oral availability.

We believe Lipid-Antiviral-Conjugate Technology-based drugs may be developed with reduced risks since they have a known mechanism of action. Preclinical studies and in vitro experiments on a number of drugs have shown specific improvements in biological activity compared with the parent drug.  CMX001 has demonstrated higher bioavailability than the parent drug cidofovir in initial human studies, and may offer a more convenient oral treatment option when compared to cidofovir, which must be delivered intravenously. Like CMX001, new drugs that utilize Chimerix’s Lipid-Antiviral-Conjugate Technology are protected as new chemical entities with strong composition of matter patents.